Loading...

ReNeuron Group

DB:RQE1
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RQE1
DB
£75M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The last earnings update was 129 days ago. More info.


Add to Portfolio Compare Print
  • ReNeuron Group has significant price volatility in the past 3 months.
RQE1 Share Price and Events
7 Day Returns
-10.7%
DB:RQE1
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
213.1%
DB:RQE1
-10.2%
DE Biotechs
-6%
DE Market
RQE1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ReNeuron Group (RQE1) -10.7% 200.7% 352.6% 213.1% -14% -14%
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • RQE1 outperformed the Biotechs industry which returned -10.2% over the past year.
  • RQE1 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
RQE1
Industry
5yr Volatility vs Market

RQE1 Value

 Is ReNeuron Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ReNeuron Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ReNeuron Group.

DB:RQE1 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:RQE1
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 19%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 6.65%)
8.87%

Discounted Cash Flow Calculation for DB:RQE1 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ReNeuron Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:RQE1 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (GBP, Millions) Source Present Value
Discounted (@ 8.87%)
2019 -17.10 Analyst x2 -15.71
2020 -20.11 Analyst x2 -16.97
2021 -25.65 Analyst x1 -19.88
2022 -22.80 Analyst x1 -16.23
2023 -2.18 Analyst x1 -1.43
2024 24.82 Analyst x1 14.90
2025 40.68 Est @ 63.91% 22.43
2026 58.90 Est @ 44.8% 29.84
2027 77.42 Est @ 31.43% 36.02
2028 94.50 Est @ 22.07% 40.39
Present value of next 10 years cash flows £73.38
DB:RQE1 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= £94.50 × (1 + 0.23%) ÷ (8.87% – 0.23%)
£1,095.67
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= £1,095.67 ÷ (1 + 8.87%)10
£468.26
DB:RQE1 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= £73.38 + £468.26
£541.64
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £541.64 / 31.66
£17.11
DB:RQE1 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:RQE1 represents 1.09091x of AIM:RENE
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.09091x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (GBP) x Listing Adjustment Factor
= £ 17.11 x 1.09091
€18.66
Value per share (EUR) From above. €18.66
Current discount Discount to share price of €2.58
= -1 x (€2.58 - €18.66) / €18.66
86.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price ReNeuron Group is available for.
Intrinsic value
>50%
Share price is €2.58 vs Future cash flow value of €18.66
Current Discount Checks
For ReNeuron Group to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • ReNeuron Group's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • ReNeuron Group's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ReNeuron Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ReNeuron Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:RQE1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in GBP £-0.42
AIM:RENE Share Price ** AIM (2019-04-18) in GBP £2.37
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ReNeuron Group.

DB:RQE1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:RENE Share Price ÷ EPS (both in GBP)

= 2.37 ÷ -0.42

-5.6x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ReNeuron Group is loss making, we can't compare its value to the Europe Biotechs industry average.
  • ReNeuron Group is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does ReNeuron Group's expected growth come at a high price?
Raw Data
DB:RQE1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.6x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
29.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ReNeuron Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ReNeuron Group's assets?
Raw Data
DB:RQE1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in GBP £1.01
AIM:RENE Share Price * AIM (2019-04-18) in GBP £2.37
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:RQE1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:RENE Share Price ÷ Book Value per Share (both in GBP)

= 2.37 ÷ 1.01

2.35x

* Primary Listing of ReNeuron Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ReNeuron Group is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess ReNeuron Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ReNeuron Group has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RQE1 Future Performance

 How is ReNeuron Group expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
29.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ReNeuron Group expected to grow at an attractive rate?
  • ReNeuron Group's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • ReNeuron Group's earnings growth is expected to exceed the Germany market average.
  • ReNeuron Group's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:RQE1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:RQE1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 29.3%
DB:RQE1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 54.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:RQE1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:RQE1 Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-03-31 39 25 1
2023-03-31 14 -2 1
2022-03-31 0 -23 1
2021-03-31 2 -23 2
2020-03-31 5 -18 -15 2
2019-03-31 2 -17 -15 2
DB:RQE1 Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-09-30 1 -15 -13
2018-06-30 1 -15 -15
2018-03-31 1 -15 -18
2017-12-31 1 -15 -18
2017-09-30 1 -14 -17
2017-06-30 1 -13 -17
2017-03-31 1 -13 -16
2016-12-31 1 -12 -15
2016-09-30 1 -12 -15
2016-06-30 1 -12 -13
2016-03-31 1 -12 -11
2015-12-31 1 -10 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ReNeuron Group's earnings are expected to grow significantly at over 20% yearly.
  • ReNeuron Group's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:RQE1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from ReNeuron Group Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RQE1 Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-03-31 0.46 0.46 0.46 1.00
2023-03-31 -0.04 -0.04 -0.04 1.00
2022-03-31 -0.43 -0.43 -0.43 1.00
2021-03-31 -0.48 -0.48 -0.48 1.00
2020-03-31 -0.42 -0.39 -0.46 2.00
2019-03-31 -0.47 -0.36 -0.57 2.00
DB:RQE1 Past Financials Data
Date (Data in GBP Millions) EPS *
2018-09-30 -0.42
2018-06-30 -0.49
2018-03-31 -0.56
2017-12-31 -0.55
2017-09-30 -0.55
2017-06-30 -0.52
2017-03-31 -0.49
2016-12-31 -0.48
2016-09-30 -0.46
2016-06-30 -0.45
2016-03-31 -0.44
2015-12-31 -0.45

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ReNeuron Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ReNeuron Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ReNeuron Group has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RQE1 Past Performance

  How has ReNeuron Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ReNeuron Group's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ReNeuron Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ReNeuron Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ReNeuron Group's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ReNeuron Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ReNeuron Group Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RQE1 Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 0.90 -13.37 4.97
2018-06-30 0.90 -15.49 4.79
2018-03-31 0.90 -17.62 4.62
2017-12-31 0.90 -17.53 4.41
2017-09-30 0.90 -17.45 4.21
2017-06-30 0.90 -16.51 4.18
2017-03-31 0.90 -15.57 4.14
2016-12-31 0.74 -15.07 4.18
2016-09-30 0.57 -14.57 4.22
2016-06-30 0.57 -12.96 4.12
2016-03-31 0.56 -11.35 4.02
2015-12-31 0.56 -10.31 4.03
2015-09-30 0.55 -9.26 4.05
2015-06-30 0.55 -9.08 3.80
2015-03-31 0.55 -8.91 3.55
2014-12-31 0.62 -8.47 3.39
2014-09-30 0.68 -8.03 3.22
2014-06-30 0.68 -7.55 2.97
2014-03-31 0.68 -7.07 2.71
2013-12-31 0.35 -6.85 2.49 -1.18
2013-09-30 0.02 -6.63 2.26 -2.37
2013-06-30 0.02 -6.49 2.29 -1.18
2013-03-31 0.02 -6.35 2.32
2012-12-31 0.02 -6.21 2.23 2.35
2012-09-30 0.02 -6.07 2.15 4.69
2012-06-30 0.03 -6.15 2.10 4.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ReNeuron Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ReNeuron Group has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ReNeuron Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ReNeuron Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ReNeuron Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RQE1 Health

 How is ReNeuron Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ReNeuron Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ReNeuron Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ReNeuron Group has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ReNeuron Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • ReNeuron Group has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ReNeuron Group Company Filings, last reported 6 months ago.

DB:RQE1 Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 31.91 0.00 30.67
2018-06-30 31.91 0.00 30.67
2018-03-31 36.67 0.00 37.41
2017-12-31 36.67 0.00 37.41
2017-09-30 44.16 0.00 45.28
2017-06-30 44.16 0.00 45.28
2017-03-31 53.16 0.00 53.06
2016-12-31 53.16 0.00 53.06
2016-09-30 60.46 0.00 60.08
2016-06-30 60.46 0.00 60.08
2016-03-31 67.66 0.00 60.71
2015-12-31 67.66 0.00 60.71
2015-09-30 74.03 0.00 72.28
2015-06-30 74.03 0.00 72.28
2015-03-31 13.14 0.00 12.38
2014-12-31 13.14 0.00 12.38
2014-09-30 17.81 0.00 16.10
2014-06-30 17.81 0.00 16.10
2014-03-31 21.72 0.00 20.92
2013-12-31 21.72 0.00 20.92
2013-09-30 25.40 0.00 23.52
2013-06-30 25.40 0.00 23.52
2013-03-31 4.91 0.00 3.55
2012-12-31 4.91 0.00 3.55
2012-09-30 8.12 0.00 6.67
2012-06-30 8.12 0.00 6.67
  • ReNeuron Group has no debt.
  • ReNeuron Group had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ReNeuron Group has sufficient cash runway for 2 years based on current free cash flow.
  • ReNeuron Group has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 14% each year.
X
Financial health checks
We assess ReNeuron Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ReNeuron Group has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RQE1 Dividends

 What is ReNeuron Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ReNeuron Group dividends. Estimated to be 0% next year.
If you bought €2,000 of ReNeuron Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ReNeuron Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ReNeuron Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:RQE1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:RQE1 Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2024-03-31
2023-03-31
2022-03-31
2021-03-31 0.00 1.00
2020-03-31 0.00 2.00
2019-03-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ReNeuron Group has not reported any payouts.
  • Unable to verify if ReNeuron Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ReNeuron Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ReNeuron Group has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of ReNeuron Group's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess ReNeuron Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ReNeuron Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ReNeuron Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RQE1 Management

 What is the CEO of ReNeuron Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Olav Hellebø
COMPENSATION £440,000
AGE 53
TENURE AS CEO 4.6 years
CEO Bio

Mr. Olav Hellebø, MBA, BBA, has been the Chief Executive Officer of ReNeuron Group plc since September 8, 2014. Mr. Hellebø served as an Executive of Aqualis ASA. He is a Co-Founder and Chairman of Palma Biotech S.L. Mr. Hellebø served as the Chief Executive Officer of Weifa ASA from February 1, 2010 to May 14, 2013. He is an experienced pharmaceutical Executive, who has held senior positions in the pharmaceutical industry in both Europe and the USA. He served as Vice President of Inflammation Operations of UCB SA. He joined Clavis Pharma from UCB, the global biopharmaceutical company, where he served as Senior Vice President of UCB Pharma and President of Immunology Operations. In this position, he builted and led the global organization, responsible for the successful registration and launch of Cimzia(R), UCB's new antibody drug for the treatment of rheumatoid arthritis and Crohn's disease. From 2003 to 2004, he served as the Chief Operating Officer of Novartis UK. He held a series of senior international roles at Schering Plough, the last as Head of Schering Plough's Oncology Biotech Division in the USA. He serves as a Director of ReNeuron Group plc. He has been a Director of Pharmalink AB since July 2014. Mr. Hellebø graduated in Business Studies and International Business Studies from Hofstra University, New York and received an MBA from IESE, Barcelona.

CEO Compensation
  • Olav's compensation has increased whilst company is loss making.
  • Olav's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the ReNeuron Group management team in years:

4
Average Tenure
55
Average Age
  • The tenure for the ReNeuron Group management team is about average.
Management Team

Olav Hellebø

TITLE
CEO & Director
COMPENSATION
£440K
AGE
53
TENURE
4.6 yrs

Michael Hunt

TITLE
CFO, Secretary & Executive Director
COMPENSATION
£299K
AGE
55
TENURE
5.3 yrs

John Sinden

TITLE
Founder & Chief Scientific Officer
COMPENSATION
£103K
AGE
67

Randolph Corteling

TITLE
Head of Research
TENURE
4 yrs

Shaun Stapleton

TITLE
Head of Regulatory Affairs
TENURE
3.8 yrs

Richard Beckman

TITLE
Chief Medical Officer
TENURE
1 yrs
Board of Directors Tenure

Average tenure and age of the ReNeuron Group board of directors in years:

7.3
Average Tenure
60
Average Age
  • The tenure for the ReNeuron Group board of directors is about average.
Board of Directors

John Berriman

TITLE
Non-Executive Chairman
COMPENSATION
£53K
AGE
70
TENURE
4.1 yrs

Olav Hellebø

TITLE
CEO & Director
COMPENSATION
£440K
AGE
53

Michael Hunt

TITLE
CFO, Secretary & Executive Director
COMPENSATION
£299K
AGE
55
TENURE
18.3 yrs

Simon Cartmell

TITLE
Non-Executive Director
COMPENSATION
£38K
AGE
58
TENURE
7.8 yrs

Mike Owen

TITLE
Chair of Scientific Advisory Board & Non-Executive Director
COMPENSATION
£26K
AGE
67
TENURE
3.3 yrs

Claudia D'Augusta

TITLE
Non-Executive Director
COMPENSATION
£21K
AGE
48
TENURE
1.6 yrs

Trevor Jones

TITLE
Member of Scientific & Strategic Advisory Group
COMPENSATION
£8K
AGE
75
TENURE
6.8 yrs

Jack Price

TITLE
Member of Scientific and Strategic Advisory Group
AGE
66

William Hiatt

TITLE
Member of Clinical Advisory Board
TENURE
9.2 yrs

Doug Losordo

TITLE
Member of Clinical Advisory Board
AGE
60
TENURE
9.2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by ReNeuron Group insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Apr 19 Buy Christopher Evans Individual 18. Apr 19 18. Apr 19 10,000 €2.65 €26,459
11. Apr 19 Buy Michael Owen Individual 11. Apr 19 11. Apr 19 4,237 €2.74 €11,600
11. Apr 19 Buy Simon Cartmell Individual 11. Apr 19 11. Apr 19 7,758 €2.62 €20,300
11. Apr 19 Buy John Berriman Individual 11. Apr 19 11. Apr 19 80,000 €2.61 €208,822
11. Apr 19 Buy Christopher Evans Individual 11. Apr 19 11. Apr 19 4,500 €2.57 €11,564
27. Sep 18 Buy Olav Hellebø Individual 27. Sep 18 27. Sep 18 14,936 €0.75 €11,219
X
Management checks
We assess ReNeuron Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ReNeuron Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RQE1 News

Simply Wall St News

RQE1 Company Info

Description

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company’s lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Details
Name: ReNeuron Group plc
RQE1
Exchange: DB
Founded: 1997
£86,331,435
31,658,664
Website: http://www.reneuron.com
Address: ReNeuron Group plc
Pencoed Business Park,
Pencoed,
CF35 5HY,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM RENE Ordinary Shares London Stock Exchange AIM Market GB GBP 12. Aug 2005
OTCPK RNUG.F Ordinary Shares Pink Sheets LLC US USD 12. Aug 2005
DB RQE1 Ordinary Shares Deutsche Boerse AG DE EUR 12. Aug 2005
AIM RENE ORD GBP0.01 London Stock Exchange AIM Market GB GBP 24. Jan 2018
Number of employees
Current staff
Staff numbers
62
ReNeuron Group employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 21:13
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2018/12/14
Last earnings reported: 2018/09/30
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.